Needham Reiterates Buy Rating on Cormedix, Keeps $15 Target
Needham reiterated its Buy rating on Cormedix and maintained a $15 price target. The target implies 106.6% upside from the October 16 close of $7.26.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.